Prosthetic Valves and Anticoagulation — Viva

Opening (30 s)

"Prosthetic Valves and Anticoagulation — give a one-line definition and the single most important immediate risk."

Model: Prosthetic heart valves are mechanical (lifelong warfarin; ACC/AHA INR of 3.0 after a mechanical mitral prosthesis, INR of 2.5 after bileaflet aortic replacement without thromboembolic risk factors, plus aspirin 81 mg in the PROACT trials) or bioprosthetic (no lifelong VKA for the valve itself; if AF, rivaroxaban 20 mg daily was non-inferior to warfarin INR 2.0 to 3.0 in RIVER). DOACs are contraindicated in any mechanical valve (RE-ALIGN stopped after 252 patients; PROACT-Xa stopped after 863 patients for excess thromboembolism with apixaban 4.2 versus 1.3 percent per patient-year). After TAVI without another anticoagulation indication, rivaroxaban 10 mg caused harm versus an antiplatelet strategy (GALILEO). Acute prosthetic valve thrombosis: anticoagulation was inadequate in 82 percent of a TEE-diagnosed series; thrombolysis was completely successful in 86 percent of treated episodes.^{[1][3][6][7][10][11][13][20]}

Station 1 — Pathophysiology (2 min)

Explain the mechanism chain from cause to clinical features and one major complication.^[1]

Station 2 — Clinical diagnosis (2 min)

Classic presentation, atypical groups, named bedside signs, and what you examine for red flags.^[1]

Red flag cue: Acute prosthetic valve thrombosis with shock — TEE; anticoagulation inadequate in 82 percent of a TEE series; thrombolysis completely successful in 86 percent of treated episodes.^[13]

Station 3 — Investigations (2 min)

First-line tests, definitive tests, and any named score with exact components.^[18]

Station 4 — Emergency management (3 min)

ABC priorities, first drugs with dose and route, procedures, and when to escalate to ICU/theatre.^[13][1]

Station 5 — Definitive / long-term care (2 min)

Stepwise definitive therapy, monitoring, complications of treatment, follow-up. ACC/AHA: after the initial post-procedure TTE, surveillance at 5 and 10 years then annually; annual TTE is reasonable after TAVI.^[1]

Station 6 — Special populations (2 min)

Child / pregnancy / elderly / immunocompromised / renal impairment — what changes. ROPAC III: uncomplicated live birth 54 percent mechanical versus 79 percent biological; valve thrombosis 6 percent; mitral OR 3.3. ACC/AHA: first-trimester warfarin carries the highest fetal risk especially when the dose exceeds 5 mg/day; if LMWH is used, target anti-Xa 0.8 to 1.2 U/ml 4 to 6 hours after the dose.^[14][1]

Station 7 — Evidence & pitfalls (2 min)

Landmark trial or guideline name if standard; three classic exam traps. RE-ALIGN and PROACT-Xa (DOAC ban); RIVER (bioprosthetic mitral plus AF); GALILEO (no routine rivaroxaban after TAVI); PERIOP2 (no routine postoperative dalteparin benefit).^{[3][20][6][7][12]}

Station 8 — Rapid-fire pearls (1 min)

Five high-yield facts a candidate must not forget under time pressure.^[1]

Examiner pass criteria

• Speaks in mechanisms and numbers, not vague lists
• Gives at least one exact dose or threshold
• Names escalation criteria
• Avoids dangerous delays (imaging when unstable, etc.)

^[1]

References20ShowHide

1. [1]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation, 2021.PMID 33332150
2. [2]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease Eur Heart J, 2022.PMID 34453165
3. [3]Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med, 2013.PMID 23991661
4. [4]Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J, 2017.PMID 29020344
5. [5]Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis N Engl J Med, 2014.PMID 24678937
6. [6]Guimarães HP, Lopes RD, de Barros E Silva PGM, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve N Engl J Med, 2020.PMID 33196155
7. [7]Dangas GD, Tijssen JGP, Wöhrle J, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement N Engl J Med, 2020.PMID 31733180
8. [8]Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J, 2015.PMID 26320109
9. [9]Jawitz OK, Wang TY, Lopes RD, et al. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve Am Heart J, 2020.PMID 32693197
10. [10]Puskas JD, Gerdisch M, Nichols D, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial J Thorac Cardiovasc Surg, 2014.PMID 24512654
11. [11]Chu MWA, Ruel M, Graeve A, et al. Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial Ann Thorac Surg, 2023.PMID 36610532
12. [12]Kovacs MJ, Wells PS, Anderson DR, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial BMJ, 2021.PMID 34108229
13. [13]Lengyel M, Vandor L The role of thrombolysis in the management of left-sided prosthetic valve thrombosis: a study of 85 cases diagnosed by transesophageal echocardiography J Heart Valve Dis, 2001.PMID 11603604
14. [14]van der Zande JA, Ramlakhan KP, Sliwa K, et al. Pregnancy with a prosthetic heart valve, thrombosis, and bleeding: the ESC EORP Registry of Pregnancy and Cardiac disease III Eur Heart J, 2026.PMID 40237423
15. [15]Ostermann H, von Heymann C Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety Expert Rev Hematol, 2019.PMID 31159607
16. [16]Jeong SI, Kim HR, Song JY, et al. Inappropriate antibiotic prophylaxis before dental procedures in congenital heart disease: Insights from a nationwide Korean cohort J Infect Public Health, 2026.PMID 41270450
17. [17]Pradhan A, Mahalawat S, Perrone MA From the INVICTUS Trial to Current Considerations: It's Not Time to Retire Vitamin K Inhibitors Yet! Pharmaceuticals (Basel), 2024.PMID 39598370
18. [18]Habets J, Tanis W, Reitsma JB, et al. Are novel non-invasive imaging techniques needed in patients with suspected prosthetic heart valve endocarditis? A systematic review and meta-analysis. Eur Radiol, 2015.PMID 25680715
19. [19]Lengyel M Management of prosthetic valve thrombosis. J Heart Valve Dis, 2004.PMID 15222276
20. [20]Wang TY, Svensson LG, Wen J, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve NEJM Evid, 2023.PMID 38320162